ATE336514T1 - Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen - Google Patents
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinenInfo
- Publication number
- ATE336514T1 ATE336514T1 AT01916083T AT01916083T ATE336514T1 AT E336514 T1 ATE336514 T1 AT E336514T1 AT 01916083 T AT01916083 T AT 01916083T AT 01916083 T AT01916083 T AT 01916083T AT E336514 T1 ATE336514 T1 AT E336514T1
- Authority
- AT
- Austria
- Prior art keywords
- life
- based fusion
- antibody
- fusion proteins
- antibodies
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18176800P | 2000-02-11 | 2000-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE336514T1 true ATE336514T1 (de) | 2006-09-15 |
Family
ID=22665708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01916083T ATE336514T1 (de) | 2000-02-11 | 2001-02-09 | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7091321B2 (de) |
| EP (1) | EP1252192B1 (de) |
| JP (2) | JP5179689B2 (de) |
| CN (1) | CN1406249B (de) |
| AT (1) | ATE336514T1 (de) |
| AU (1) | AU4314801A (de) |
| CA (1) | CA2399832C (de) |
| CY (1) | CY1105725T1 (de) |
| DE (1) | DE60122286T2 (de) |
| DK (1) | DK1252192T3 (de) |
| ES (1) | ES2269366T3 (de) |
| HU (1) | HUP0204475A2 (de) |
| MX (1) | MXPA02007733A (de) |
| NO (1) | NO20023774L (de) |
| PT (1) | PT1252192E (de) |
| WO (1) | WO2001058957A2 (de) |
Families Citing this family (274)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1037927T3 (da) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US7387772B1 (en) * | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MX353234B (es) | 1999-01-15 | 2018-01-08 | Genentech Inc | Variantes de polipeptidos con función efectora alterada. |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CZ20014123A3 (cs) * | 1999-05-19 | 2002-06-12 | Lexigen Pharmaceuticals Corp. | Exprese a export interferonů-alfa jako Fc fúzních proteinů |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| RU2263118C2 (ru) | 1999-08-09 | 2005-10-27 | Лексиген Фармасьютикэлс Корп. | Комплексы антител с несколькими цитокинами |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
| CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
| CA2412845C (en) * | 2000-06-29 | 2014-07-22 | Lexigen Pharmaceuticals Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| PL206701B1 (pl) | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| WO2002090566A2 (en) | 2001-05-03 | 2002-11-14 | Merck Patent Gmbh | Recombinant tumor specific antibody and use thereof |
| CA2469151C (en) * | 2001-12-04 | 2013-08-13 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Immunocytokines with modulated selectivity |
| ES2289303T3 (es) * | 2002-02-06 | 2008-02-01 | Ares Trading S.A. | Factor de necrosis tumoral combinado con interferon en enfermedades desmielinantes. |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US8809504B2 (en) * | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1572748E (pt) | 2002-12-17 | 2010-09-28 | Merck Patent Gmbh | Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2 |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| DK1624891T4 (da) | 2003-05-06 | 2013-07-15 | Biogen Idec Hemophilia Inc | Kimære koagulationsfaktor Fc proteiner til behandling af hæmofili |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| AU2004309050B2 (en) | 2003-12-30 | 2010-10-14 | Merck Patent Gmbh | IL-7 fusion proteins |
| DK1699821T3 (da) | 2003-12-31 | 2012-07-16 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER |
| WO2005066348A2 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| CA2553883C (en) * | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| AU2005274905B2 (en) | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| JP2008510007A (ja) * | 2004-08-16 | 2008-04-03 | メディミューン，インコーポレーテッド | 抗体依存性細胞性細胞傷害活性が増強されたＥｐｈ受容体Ｆｃ変異体 |
| EP1819728B1 (de) * | 2004-12-09 | 2010-04-21 | MERCK PATENT GmbH | Il-7-varianten mit reduzierter immunogenität |
| CN100429233C (zh) * | 2005-02-03 | 2008-10-29 | 上海长海医院 | 一种重组融合蛋白及其制备方法及用途 |
| EP1853718B1 (de) | 2005-02-15 | 2015-08-05 | Duke University | Anti-cd19-antikörper und ihre verwendung in der onkologie |
| AU2006239851B2 (en) * | 2005-04-26 | 2011-06-16 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| WO2006121852A2 (en) | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
| EP1899477A4 (de) | 2005-07-01 | 2010-01-20 | Medimmune Inc | Integrierter ansatz zur erzeugung von heilmitteln mit multidomänen-proteinen |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| EP1943332A4 (de) | 2005-10-14 | 2011-04-13 | Medimmune Inc | Zellpräsentation von antikörperbibliotheken |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| WO2007133250A2 (en) * | 2005-10-31 | 2007-11-22 | Austin Gurney | Compositions and methods for diagnosing and treating cancer |
| DK1966238T3 (da) * | 2005-12-30 | 2012-07-16 | Merck Patent Gmbh | INTERLEUKIN-12P40-varianter med forbedret stabilitet |
| DK1966245T3 (da) * | 2005-12-30 | 2011-07-18 | Merck Patent Gmbh | Anti-CD19-Antistoffer med reduceret immunogenicitet |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| EP1816201A1 (de) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
| WO2007103469A2 (en) | 2006-03-06 | 2007-09-13 | Aeres Biomedical Ltd. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| JP5368301B2 (ja) | 2006-06-22 | 2013-12-18 | ノボ・ノルデイスク・エー／エス | 可溶性ヘテロ二量体レセプター及びその使用 |
| EP1873166B1 (de) * | 2006-06-30 | 2010-09-08 | CONARIS research institute AG | Verbesserte sgp 130Fc Dimere |
| EP2038417A2 (de) * | 2006-07-06 | 2009-03-25 | Merck Patent GmbH | Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen |
| EP1878747A1 (de) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-hergestellte Antikörper |
| TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| TW200819463A (en) * | 2006-09-08 | 2008-05-01 | Genentech Inc | Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders |
| US8754194B2 (en) | 2006-12-22 | 2014-06-17 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| EP2737907A3 (de) | 2007-05-07 | 2014-11-05 | MedImmune, LLC | Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen |
| CN105131127B (zh) * | 2007-05-30 | 2018-09-07 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| CN105175553B (zh) * | 2007-05-30 | 2019-11-22 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| EP1997830A1 (de) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung |
| US20110077383A1 (en) * | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
| AR067536A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
| AR067537A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Purificacion de polipeptidos pegilados |
| US20090022720A1 (en) | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
| WO2009018386A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| EP3211010A1 (de) | 2007-12-21 | 2017-08-30 | Medimmune Limited | Bindungselemente für interleukin-4-rezeptor-alpha (il-4r) - 173 |
| AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
| US9404928B2 (en) * | 2008-02-05 | 2016-08-02 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
| MX2010011470A (es) * | 2008-04-18 | 2010-11-12 | Abbott Lab | Estimacion in vitro de la vida in vivo de proteinas de enalce. |
| TWI506037B (zh) * | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
| EP2373689A1 (de) | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Kristalle und struktur einer humanen igg-fc-variante mit verst?rkter fcrn-bindung |
| AU2010206840B2 (en) | 2009-01-21 | 2015-02-05 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| BRPI1016204A2 (pt) | 2009-04-22 | 2016-04-19 | Merck Patent Gmbh | proteínas de fusão de anticorpos com sítios de ligação fcrn modificados |
| WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| EP2467156B1 (de) | 2009-08-17 | 2017-11-01 | Tracon Pharmaceuticals, Inc. | Kombinations-krebstherapie mit anti-endoglin-antikörpern und anti-vegf-mitteln |
| WO2011028228A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| LT2486141T (lt) | 2009-10-07 | 2018-05-25 | Macrogenics, Inc. | Fc regioną turintys polipeptidai, pasižymintys pagerinta efektorine funkcija dėl fukozilinimo laipsnio pasikeitimų, ir jų naudojimo būdai |
| IN2012DN05169A (de) * | 2009-12-02 | 2015-10-23 | Acceleron Pharma Inc | |
| EP2506868B1 (de) | 2009-12-06 | 2017-11-15 | Bioverativ Therapeutics Inc. | Chimäre und hybride faktor-viii-fc-polypeptide und verfahren zu ihrer anwendung |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| ES2678143T3 (es) | 2010-01-19 | 2018-08-09 | President And Fellows Of Harvard College | Opsonina obtenida por ingeniería genética para la detección y el tratamiento de microorganismos patógenos |
| WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
| JP2013530929A (ja) | 2010-04-01 | 2013-08-01 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ｆｒｉｚｚｌｅｄ結合剤およびその使用 |
| WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
| MY192639A (en) | 2010-07-09 | 2022-08-29 | Bioverativ Therapeutics Inc | Factor ix polypeptides and methods of use thereof |
| WO2012020096A1 (en) | 2010-08-13 | 2012-02-16 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| WO2012035037A1 (en) | 2010-09-14 | 2012-03-22 | F. Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
| US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
| HUE033008T2 (hu) | 2011-04-13 | 2017-11-28 | Bristol Myers Squibb Co | FC fúziós proteinek, amelyek tartalmaznak új linkereket |
| CN103857699B (zh) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| WO2012170938A1 (en) | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
| EP2537933A1 (de) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine |
| US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US9382305B2 (en) | 2011-07-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| KR102110736B1 (ko) | 2011-07-08 | 2020-05-14 | 바이오버라티브 테라퓨틱스 인크. | Viii 인자 키메라 및 하이브리드 폴리펩타이드, 그리고 이들의 사용 방법 |
| MX2014000316A (es) | 2011-07-08 | 2014-02-19 | Bayer Ip Gmbh | Proteinas de fusion liberadoras de relaxina y usos de las mismas. |
| EP2737311B1 (de) | 2011-07-25 | 2020-12-02 | Bioverativ Therapeutics Inc. | Tests zur überwachung von blutungsstörungen |
| PT2760471T (pt) | 2011-09-30 | 2017-03-22 | Dana Farber Cancer Inst Inc | Péptidos terapêuticos |
| EP3559049A4 (de) | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptidkonstrukte und anwendungen davon |
| WO2013070565A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| EP3453402B1 (de) | 2012-01-12 | 2021-07-21 | Bioverativ Therapeutics Inc. | Reduzierung der immunogenität gegen den faktor viii bei patienten in einer faktor-viii-therapie |
| EP3564260B1 (de) | 2012-02-15 | 2022-10-19 | Bioverativ Therapeutics Inc. | Faktor-viii-zusammensetzungen und verfahren zur herstellung und verwendung davon |
| EP2822577B1 (de) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Rekombinante faktor-viii-proteine |
| WO2013134138A1 (en) * | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| RU2636342C2 (ru) | 2012-04-30 | 2017-11-22 | Биокон Лимитед | Нацеленные/иммуномодулирующие слитые белки и способы их получения |
| HRP20211641T1 (hr) | 2012-07-13 | 2022-02-04 | Roche Glycart Ag | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti |
| DK3381943T3 (da) | 2012-07-25 | 2022-05-16 | Celldex Therapeutics Inc | Anti-kit-antistoffer og anvendelser deraf |
| ES2633894T3 (es) | 2012-08-02 | 2017-09-25 | F. Hoffmann-La Roche Ag | Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| TWI750197B (zh) | 2012-09-25 | 2021-12-21 | 美商百歐維拉提夫治療公司 | Ｆｉｘ多肽的應用 |
| CA2888806A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
| WO2014066328A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| EP3446700A1 (de) | 2012-10-30 | 2019-02-27 | Bioverativ Therapeutics Inc. | Verfahren zur verwendung von fviii-polypeptid |
| WO2014121196A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
| US10183967B2 (en) | 2013-02-12 | 2019-01-22 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| ES2751735T3 (es) | 2013-02-12 | 2020-04-01 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
| US9657098B2 (en) | 2013-03-15 | 2017-05-23 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
| EP3666886A1 (de) | 2013-03-15 | 2020-06-17 | Dana-Farber Cancer Institute, Inc. | Therapeutische peptide |
| HUE047933T2 (hu) | 2013-03-15 | 2020-05-28 | Bioverativ Therapeutics Inc | Faktor VIII polipeptid készítmények |
| EP2968541A4 (de) | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Multivalente und monovalente multispezifische komplexe und deren verwendungen |
| KR20150145260A (ko) | 2013-04-19 | 2015-12-29 | 싸이튠 파마 | 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료 |
| PT3677591T (pt) | 2013-04-29 | 2023-02-17 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| AU2014268603B2 (en) | 2013-05-21 | 2018-03-22 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
| WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
| EP3733244A1 (de) | 2013-10-02 | 2020-11-04 | Medlmmune, LLC | Neutralisierende antiinflueanza-a-virus-antikörper und verwendungen davon |
| EP4332839A3 (de) | 2013-12-06 | 2024-06-05 | Bioverativ Therapeutics Inc. | Pharmakokinetische werkzeuge für populationen und verwendungen davon |
| KR20160090904A (ko) | 2013-12-06 | 2016-08-01 | 다나-파버 캔서 인스티튜트 인크. | 치료 펩티드 |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| EP3546474B1 (de) | 2013-12-18 | 2021-07-07 | President and Fellows of Harvard College | Crp-erfassung/-detektion von grampositiven bakterien |
| KR102452173B1 (ko) | 2013-12-24 | 2022-10-17 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | Fcrn 길항제 및 사용방법 |
| NZ721364A (en) | 2014-02-10 | 2023-04-28 | Merck Patent Gmbh | Targeted tgfβ inhibition |
| EP2915569A1 (de) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN106456728A (zh) | 2014-03-14 | 2017-02-22 | 达纳－法伯癌症研究所公司 | 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法 |
| KR102385372B1 (ko) | 2014-03-24 | 2022-04-11 | 바이오버라티브 테라퓨틱스 인크. | 동결건조된 ix 인자 제형 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| CA2961917A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| SG11201703251TA (en) | 2014-10-29 | 2017-05-30 | Teva Pharmaceuticals Australia Pty Ltd | INTERFERON α2B VARIANTS |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| CN107250157B (zh) | 2014-11-21 | 2021-06-29 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
| ME03806B (de) | 2014-11-21 | 2021-04-20 | Bristol Myers Squibb Co | Antikörper gegen cd73 und verwendungen davon |
| CA2969314A1 (en) | 2014-12-01 | 2016-06-09 | Ferring B.V. | Selective il-6-trans-signalling inhibitor compositions |
| JP6775513B2 (ja) | 2014-12-01 | 2020-10-28 | フェリング・ベー・フェー | 選択的ｉｌ−６−トランス−シグナル伝達阻害剤の投与 |
| MX2017007744A (es) | 2014-12-23 | 2017-09-05 | Bristol Myers Squibb Co | Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit). |
| EP4006051A1 (de) | 2015-03-09 | 2022-06-01 | Argenx BVBA | Verfahren zur reduzierung der serumspiegel von fc-haltigen wirkstoffen unter verwendung von fcrn-antagonisten |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| SI3303396T1 (sl) | 2015-05-29 | 2023-01-31 | Bristol-Myers Squibb Company | Protitelesa proti OX40 in njihova uporaba |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| TWI762879B (zh) | 2015-07-30 | 2022-05-01 | 美商宏觀基因股份有限公司 | Pd-1結合分子和其使用方法 |
| AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
| CN108289928B (zh) | 2015-08-06 | 2024-09-17 | 哈佛大学校长及研究员协会 | 改进的微生物-结合分子和其用途 |
| GEP20217317B (en) | 2015-10-08 | 2021-11-10 | Macrogenics Inc | Combination therapy for the treatment of cancer |
| KR20180082563A (ko) | 2015-11-19 | 2018-07-18 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 |
| EA201891178A1 (ru) | 2015-12-14 | 2019-01-31 | Макродженикс, Инк. | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения |
| UY37127A (es) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| BR112018067368A2 (pt) | 2016-03-04 | 2019-01-15 | Bristol-Myers Squibb Company | terapia de combinação com anticorpos anti-cd73 |
| US20190077870A1 (en) | 2016-03-16 | 2019-03-14 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
| BR112018071105A2 (pt) | 2016-04-15 | 2019-02-26 | Macrogenics, Inc. | conjugado de droga e anticorpo, molécula de ligação, composição farmacêutica e uso |
| EA039084B1 (ru) | 2016-05-09 | 2021-12-01 | Бристол-Майерс Сквибб Компани | Антитела к tl1a и их применения |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3471754A1 (de) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1-antikörper |
| KR102493282B1 (ko) | 2016-07-14 | 2023-02-01 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| EP3484911B1 (de) | 2016-07-15 | 2020-11-04 | H. Hoffnabb-La Roche Ag | Verfahren zur reinigung von pegyliertem erythropoetin |
| RU2019106663A (ru) | 2016-08-12 | 2020-09-14 | Мерк Патент Гмбх | Комбинированная терапия рака |
| WO2018044970A1 (en) | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
| EP3534947A1 (de) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren |
| PE20200012A1 (es) | 2016-11-23 | 2020-01-06 | Bioverativ Therapeutics Inc | Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x |
| IL266972B2 (en) | 2016-12-02 | 2024-04-01 | Bioverativ Therapeutics Inc | Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors |
| AU2017368328A1 (en) | 2016-12-02 | 2019-07-18 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN110267685B (zh) | 2016-12-23 | 2023-06-20 | 伊缪诺金公司 | 靶向adam9的免疫缀合物及其使用方法 |
| US11242402B2 (en) | 2016-12-23 | 2022-02-08 | Macrogenics, Inc. | ADAM9-binding molecules, and methods of use thereof |
| WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| SG11201906947SA (en) | 2017-02-17 | 2019-08-27 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof |
| IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| US11524985B2 (en) * | 2017-03-20 | 2022-12-13 | Bio-Techne Corporation | IL-37 fusion protein and methods of making and using same |
| US11168129B2 (en) | 2017-05-15 | 2021-11-09 | University Of Rochester | Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof |
| WO2018218056A1 (en) | 2017-05-25 | 2018-11-29 | Birstol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| EP3694552A1 (de) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap-antikörper und verwendungen davon |
| BR112020007309A2 (pt) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos |
| PH12020550661A1 (en) | 2017-11-21 | 2021-04-19 | Univ Leland Stanford Junior | Partial agonists of interleukin-2 |
| US12240875B2 (en) | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| KR102722731B1 (ko) | 2017-12-19 | 2024-10-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| US12129297B2 (en) | 2018-01-12 | 2024-10-29 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
| KR20200121834A (ko) | 2018-02-15 | 2020-10-26 | 마크로제닉스, 인크. | 변이체 cd3-결합 도메인 및 질환 치료를 위한 병용 요법에서의 그것의 용도 |
| KR20200135421A (ko) | 2018-03-21 | 2020-12-02 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| MX2020009861A (es) | 2018-03-23 | 2020-10-08 | Bristol Myers Squibb Co | Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos. |
| JOP20200240A1 (ar) | 2018-04-02 | 2020-09-27 | Bristol Myers Squibb Co | أجسام مضادة ضد- trem-1 واستخداماتها |
| US11958895B2 (en) | 2018-05-03 | 2024-04-16 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
| MX2020012397A (es) | 2018-05-18 | 2021-04-12 | Bioverativ Therapeutics Inc | Metodos de tratamiento de la hemofilia a. |
| CA3101462A1 (en) | 2018-06-08 | 2019-12-12 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
| SG11202012257VA (en) | 2018-06-26 | 2021-01-28 | Immunogen Inc | Immunoconjugates targeting adam9 and methods of use thereof |
| EP3820904A2 (de) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | An ilt4 bindende antikörper |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| BR112021000303A2 (pt) | 2018-07-11 | 2021-04-13 | Five Prime Therapeutics, Inc. | Anticorpos que se ligam a vista em ph ácido |
| US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| TW202035445A (zh) | 2018-10-10 | 2020-10-01 | 美商帝洛斯療法股份有限公司 | 抗lap抗體變異體及其用途 |
| TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| WO2020093024A2 (en) | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Methods of administering anti-tim-3 antibodies |
| CN113272017A (zh) | 2018-11-01 | 2021-08-17 | 默克专利有限公司 | 抗tim-3抗体 |
| CN113348177A (zh) | 2018-11-28 | 2021-09-03 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
| US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| EP3883966B1 (de) | 2018-12-21 | 2023-07-12 | OSE Immunotherapeutics | Humanisierter anti-human-pd-1-antikörper und seine verwendung bei krebs und infektionskrankheiten |
| US20220025050A1 (en) | 2018-12-21 | 2022-01-27 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
| CN113574067A (zh) | 2018-12-21 | 2021-10-29 | Ose免疫疗法公司 | 双功能抗PD-1/SIRPα分子 |
| BR112021012037A2 (pt) | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula anti-pd-1/il-7 bifuncional |
| BR112021014106A2 (pt) | 2019-01-22 | 2021-10-13 | Bristol-Myers Squibb Company | Anticorpos contra subunidade alfa de il-7r e usos dos mesmos |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| EP3927728A2 (de) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Ungezielte und zielgerichtete il-10-fc-fusionsproteine |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| AU2020279112A1 (en) | 2019-05-17 | 2021-12-02 | Xencor, Inc. | IL-7-Fc-fusion proteins |
| PH12021552847A1 (en) | 2019-06-07 | 2023-01-16 | Argenx Bvba | PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION |
| US20220332817A1 (en) | 2019-07-15 | 2022-10-20 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
| CN114174536A (zh) | 2019-07-15 | 2022-03-11 | 百时美施贵宝公司 | 抗trem-1抗体及其用途 |
| CA3149719A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| CN115916233A (zh) | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| WO2021140202A1 (en) | 2020-01-08 | 2021-07-15 | argenx BV | Methods for treating pemphigus disorders |
| CN115315436A (zh) | 2020-01-10 | 2022-11-08 | 明峰治疗股份公司 | 修饰的il-2多肽及其用途 |
| KR20240046306A (ko) | 2020-01-14 | 2024-04-08 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
| US20230107644A1 (en) | 2020-04-01 | 2023-04-06 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| EP4132971A1 (de) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinitätsgereifte anti-lap-antikörper und verwendungen davon |
| EP3921034A2 (de) | 2020-04-28 | 2021-12-15 | The Rockefeller University | Neutralisierende anti-sars-cov-2-antikörper und verfahren zu deren verwendung |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| EP4175650A1 (de) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelinisoformbindende moleküle und chimäre pd1-rezeptormoleküle, zellen damit und verwendungen davon |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TW202227481A (zh) | 2020-11-04 | 2022-07-16 | 美國洛克菲勒大學 | 中和抗sars-cov-2抗體 |
| WO2022108627A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
| MX2023007301A (es) | 2020-12-17 | 2023-07-04 | Ose Immunotherapeutics | Moleculas bifuncionales anti-pd1/il-7. |
| EP4265637A4 (de) | 2020-12-18 | 2025-01-15 | Zhuhai Trinomab Pharmaceutical Co Ltd | Für respiratorisches synzytialvirus spezifisches bindungsmolekül |
| US12060411B2 (en) | 2021-01-15 | 2024-08-13 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies |
| EP4314068A1 (de) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antikörper gegen gespaltenes cdcp1 und verwendungen davon |
| IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | A new scaffold for bifunctional molecules with improved properties |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2023281484A1 (en) * | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Synthetic il-7 and il-7 immunocytokines |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| KR20240040134A (ko) * | 2021-07-09 | 2024-03-27 | 브라이트 피크 테라퓨틱스 아게 | 항체 접합체 및 이의 제조 |
| WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
| AU2023291783A1 (en) | 2022-06-15 | 2024-12-12 | argenx BV | Fcrn binding molecules and methods of use |
| KR20250036813A (ko) | 2022-07-12 | 2025-03-14 | 싸이톰스 테라퓨틱스, 인크. | Epcam 면역접합체 및 이의 용도 |
| AR129991A1 (es) | 2022-07-22 | 2024-10-23 | Bristol Myers Squibb Co | Anticuerpos que se unen a la pad4 humana y usos de los mismos |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024186635A2 (en) | 2023-03-03 | 2024-09-12 | Celldex Therapeutics, Inc. | Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
Family Cites Families (227)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| US5082658A (en) | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
| EP0158198A1 (de) | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA und ihre Verwendung |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
| US5643565A (en) | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
| DE3712985A1 (de) | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
| JPS63267278A (ja) | 1986-03-14 | 1988-11-04 | Toray Ind Inc | インタ−フエロン結合体を暗号化する塩基配列 |
| EP0237019A3 (de) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Konjugiertes Interferon und dessen Herstellung unter Verwendung eines rekombinanten Gens |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DK173067B1 (da) * | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4894227A (en) | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5508031A (en) | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
| US4732683A (en) | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| EP0307434B2 (de) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Geänderte antikörper |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DE3853740T2 (de) | 1987-06-10 | 1995-11-09 | Dana Farber Cancer Inst Inc | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen. |
| US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
| PH26813A (en) | 1987-09-02 | 1992-11-05 | Ciba Geigy Ag | Conjugates of cytokines with immunoglobulins |
| JP2755395B2 (ja) | 1987-09-23 | 1998-05-20 | ブリストル―マイアーズ スクイブ コムパニー | Ｈｉｖ感染細胞に殺作用する抗体異種結合体 |
| NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
| AU2635088A (en) | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
| US5120525A (en) | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
| DE3812605A1 (de) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| IL91933A (en) | 1988-10-11 | 1994-12-29 | Univ Southern California | Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue |
| US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US6750329B1 (en) | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
| EP0406857B1 (de) | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteine und deren Herstellung |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| ATE152174T1 (de) | 1989-09-20 | 1997-05-15 | Abbott Lab | Verfahren zur herstellung von fusionsproteinen |
| KR100221066B1 (ko) | 1989-10-13 | 1999-10-01 | 스튜어트 엘.왓트 | 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물 |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| ATE369383T1 (de) | 1989-12-22 | 2007-08-15 | Hoffmann La Roche | Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0517754A1 (de) | 1990-03-02 | 1992-12-16 | Repligen Corporation | Antikörper mit erhöhter bindungsaffinität |
| ATE158615T1 (de) | 1990-03-20 | 1997-10-15 | Univ Columbia | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| US7253264B1 (en) * | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| CA2082804A1 (en) | 1990-07-27 | 1992-01-28 | Theodore Maione | Methods and compositions for treatment of angiogenic diseases |
| WO1992008495A1 (en) | 1990-11-09 | 1992-05-29 | Abbott Biotech, Inc. | Cytokine immunoconjugates |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| CA2095842A1 (en) | 1990-11-09 | 1992-05-10 | Stephen D. Gillies | Bridging antibody fusion constructs |
| EP0561907B1 (de) | 1990-12-05 | 1998-09-02 | Novo Nordisk A/S | Proteine mit geänderten epitopen und verfahren zur deren herstellung |
| US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
| EP0519596B1 (de) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| WO1993003157A1 (en) | 1991-07-29 | 1993-02-18 | Dana Farber Cancer Institute | Plasmids for the rapid preparation of modified proteins |
| ATE173763T1 (de) | 1991-08-30 | 1998-12-15 | Hutchinson Fred Cancer Res | Hybride cytokine |
| US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
| US5376367A (en) | 1991-11-22 | 1994-12-27 | Immunex Corporation | Fusion proteins comprising MGF and IL-3 |
| US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| WO1993020185A1 (en) | 1992-04-01 | 1993-10-14 | Steinman Ralph M | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| ES2215991T3 (es) | 1992-04-01 | 2004-10-16 | The Rockefeller University | Procedimiento para la proliferacion (in vitro) de precursores de celulas dendriticas y su uso para producir inmunogenos. |
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| DE4228839A1 (de) * | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
| DE69232604T2 (de) | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | Antikörperkonstrukte |
| DK0668777T3 (da) | 1992-11-05 | 2007-02-19 | Sloan Kettering Inst Cancer | Prostataspecifikt membran-antigen |
| US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
| US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| AU6816194A (en) | 1993-04-20 | 1994-11-08 | Robinson, William S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
| AU6709794A (en) | 1993-04-21 | 1994-11-08 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
| US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
| WO1994025609A1 (en) | 1993-04-28 | 1994-11-10 | Hybritech Incorporated | Method for creating optimized regulatory regions affecting protein expression and protein trafficking |
| CZ286046B6 (cs) | 1993-04-29 | 1999-12-15 | Abbott Laboratories | Přípravky na bázi analogů erythropoietinu a způsoby jejich přípravy a farmaceutické přípravky s jejich obsahem |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
| GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
| IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| AU689214B2 (en) | 1994-02-01 | 1998-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fusion proteins that include antibody and nonantibody portions |
| WO1995028427A1 (en) | 1994-04-15 | 1995-10-26 | Imclone Systems Incorporated | Chimeric interleukin-3/mutein interleukin-6 lymphokine |
| US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| HUT76095A (en) | 1994-04-26 | 1997-06-30 | Childrens Medical Center | Angiostatin and method of use for inhibition of angiogenesis |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| ES2162917T3 (es) | 1994-05-13 | 2002-01-16 | Biovation Ltd | Mejoras en o relativas al suministro de peptidos. |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| EP0770135A1 (de) | 1994-07-29 | 1997-05-02 | Smithkline Beecham Plc | Neuartige verbindungen |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| DK0706799T3 (da) | 1994-09-16 | 2002-02-25 | Merck Patent Gmbh | Immunkonjugater II |
| JPH11501506A (ja) * | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| CA2214629C (en) | 1995-03-10 | 2001-07-10 | Genentech, Inc. | Receptor activation by gas6 |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996031526A1 (en) | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| AU5893796A (en) | 1995-06-07 | 1996-12-30 | Novo Nordisk A/S | Modification of polypeptides |
| AU5985996A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| PL324284A1 (en) | 1995-06-30 | 1998-05-11 | Lilly Co Eli | Methods of treating diabetes |
| US6406689B1 (en) | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
| US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| CN1202932A (zh) | 1995-10-23 | 1998-12-23 | 儿童医学中心公司 | 治疗用抗血管生成的组合物和方法 |
| AU1407997A (en) | 1995-12-01 | 1997-06-19 | Beth Israel Hospital | Il-12 p40 subunit fusion polypeptides and uses thereof |
| AU1520097A (en) | 1995-12-27 | 1997-07-28 | Genentech Inc. | Ob protein derivatives having prolonged half-life |
| US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| WO1997030089A1 (en) | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
| US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6046310A (en) | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
| EP0904107B1 (de) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| CA2205757C (en) | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
| WO1998000127A1 (en) | 1996-07-02 | 1998-01-08 | Bar-Ilan University | Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
| WO1998006752A1 (en) | 1996-08-16 | 1998-02-19 | The Rockefeller University | A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway |
| DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
| ES2280083T3 (es) | 1996-12-20 | 2007-09-01 | Amgen Inc. | Composiciones de proteinas de fusion ob y metodos. |
| US6737057B1 (en) | 1997-01-07 | 2004-05-18 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6171588B1 (en) | 1997-04-11 | 2001-01-09 | G. D. Searle & Company | Anti-αvβ3 integrin antibody antagonists |
| AU7132798A (en) | 1997-04-17 | 1998-11-11 | Amgen, Inc. | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| AU8182298A (en) | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
| BR9812267B1 (pt) | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
| DK1037927T3 (da) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
| US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| JP2002505086A (ja) | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | 抗体ベースの融合タンパク質の循環半減期の増強 |
| CZ20003767A3 (cs) | 1998-04-15 | 2002-01-16 | Lexigen Pharmaceuticals Corp. | Kompozice pro indukci imunitní odpovědi vůči zvolenému typu buňek v organismu savce a její pouľití pro výrobu léčiva |
| RU2217168C2 (ru) | 1998-04-17 | 2003-11-27 | Лексиген Фармасьютикэлс Корпорейшн | Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора простагландина |
| WO1999054484A1 (en) * | 1998-04-20 | 1999-10-28 | The Regents Of The University Of California | Modified immunoglobulin molecules and methods for use thereof |
| WO1999058662A1 (fr) | 1998-05-14 | 1999-11-18 | Merck Patent Gmbh | Proteine fusionnee |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| AU4414099A (en) | 1998-06-03 | 1999-12-20 | Children's Medical Center Corporation | Protein oligomer compositions comprising endostatin protein and methods of usingthe same |
| EP1088084B1 (de) | 1998-06-15 | 2006-09-13 | GTC Biotherapeutics, Inc. | Erythropoietin-analog-menschliches serum-albumin fusionsprotein |
| GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| EP1105427A2 (de) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Herstellung von modifizierten molekülen mit mit erhöhten halbwertszeiten |
| CA2339331C (en) | 1998-08-25 | 2011-03-01 | Lexigen Pharmaceuticals Corporation | Expression and export of angiogenesis inhibitors as immunofusins |
| US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
| US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
| CN101703760A (zh) | 1998-10-23 | 2010-05-12 | 安姆根有限公司 | 用于预防和治疗贫血的方法以及组合物 |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| JP2002534962A (ja) | 1999-01-07 | 2002-10-22 | レキシジェン ファーマシューティカルズ コーポレイション | Ｆｃ融合タンパク質としての抗肥満症タンパク質の発現および輸送 |
| ATE418340T1 (de) | 1999-05-06 | 2009-01-15 | Univ Wake Forest | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen |
| JP3660880B2 (ja) | 1999-05-07 | 2005-06-15 | ジェネンテック・インコーポレーテッド | 新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸 |
| US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| CZ20014123A3 (cs) | 1999-05-19 | 2002-06-12 | Lexigen Pharmaceuticals Corp. | Exprese a export interferonů-alfa jako Fc fúzních proteinů |
| WO2000078334A1 (en) | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
| PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| RU2263118C2 (ru) * | 1999-08-09 | 2005-10-27 | Лексиген Фармасьютикэлс Корп. | Комплексы антител с несколькими цитокинами |
| JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
| US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
| ATE526039T1 (de) | 2000-02-24 | 2011-10-15 | Philogen Spa | Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| MXPA02011016A (es) | 2000-05-12 | 2004-03-16 | Neose Technologies Inc | Glicopeptidos recombinantes de glucolisacion in vitro. |
| CA2412845C (en) | 2000-06-29 | 2014-07-22 | Lexigen Pharmaceuticals Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| KR20030067755A (ko) | 2001-01-18 | 2003-08-14 | 메르크 파텐트 게엠베하 | 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질 |
| KR20040074587A (ko) | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
| PL206701B1 (pl) | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| WO2002090566A2 (en) | 2001-05-03 | 2002-11-14 | Merck Patent Gmbh | Recombinant tumor specific antibody and use thereof |
| JP2005507870A (ja) | 2001-08-13 | 2005-03-24 | ユニバーシティ・オブ・サザン・カリフォルニア | 低毒性のインターロイキン−２突然変異体 |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| CA2469151C (en) | 2001-12-04 | 2013-08-13 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Immunocytokines with modulated selectivity |
| CA2479212A1 (en) | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| PT1572748E (pt) | 2002-12-17 | 2010-09-28 | Merck Patent Gmbh | Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2 |
| US20050069521A1 (en) | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| JP2007531707A (ja) * | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| AU2004309050B2 (en) | 2003-12-30 | 2010-10-14 | Merck Patent Gmbh | IL-7 fusion proteins |
| DK1699821T3 (da) | 2003-12-31 | 2012-07-16 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER |
| CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| EP1819728B1 (de) | 2004-12-09 | 2010-04-21 | MERCK PATENT GmbH | Il-7-varianten mit reduzierter immunogenität |
| US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| DK1966238T3 (da) | 2005-12-30 | 2012-07-16 | Merck Patent Gmbh | INTERLEUKIN-12P40-varianter med forbedret stabilitet |
| DK1966245T3 (da) | 2005-12-30 | 2011-07-18 | Merck Patent Gmbh | Anti-CD19-Antistoffer med reduceret immunogenicitet |
| PT1966244E (pt) | 2005-12-30 | 2012-05-17 | Merck Patent Gmbh | Anticorpos anti-il-6 impedindo a ligação da il-6 complexada com il-6ralfa a gp130 |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| EP2038417A2 (de) | 2006-07-06 | 2009-03-25 | Merck Patent GmbH | Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen |
| US7622522B2 (en) | 2007-09-27 | 2009-11-24 | Sabic Innovative Plastics Ip B.V. | Flame-retardant poly(arylene ether) composition and its use as a covering for coated wire |
-
2001
- 2001-02-09 CA CA2399832A patent/CA2399832C/en not_active Expired - Lifetime
- 2001-02-09 AT AT01916083T patent/ATE336514T1/de active
- 2001-02-09 MX MXPA02007733A patent/MXPA02007733A/es active IP Right Grant
- 2001-02-09 JP JP2001558103A patent/JP5179689B2/ja not_active Expired - Fee Related
- 2001-02-09 AU AU4314801A patent/AU4314801A/xx active Pending
- 2001-02-09 DE DE60122286T patent/DE60122286T2/de not_active Expired - Lifetime
- 2001-02-09 CN CN018058639A patent/CN1406249B/zh not_active Expired - Lifetime
- 2001-02-09 ES ES01916083T patent/ES2269366T3/es not_active Expired - Lifetime
- 2001-02-09 HU HU0204475A patent/HUP0204475A2/hu unknown
- 2001-02-09 PT PT01916083T patent/PT1252192E/pt unknown
- 2001-02-09 DK DK01916083T patent/DK1252192T3/da active
- 2001-02-09 WO PCT/US2001/004455 patent/WO2001058957A2/en active IP Right Grant
- 2001-02-09 EP EP01916083A patent/EP1252192B1/de not_active Expired - Lifetime
- 2001-02-09 US US09/780,668 patent/US7091321B2/en not_active Expired - Lifetime
-
2002
- 2002-08-09 NO NO20023774A patent/NO20023774L/no not_active Application Discontinuation
-
2005
- 2005-11-07 US US11/268,191 patent/US7507406B2/en not_active Expired - Lifetime
-
2006
- 2006-10-24 CY CY20061101528T patent/CY1105725T1/el unknown
-
2009
- 2009-01-27 US US12/360,682 patent/US7790415B2/en not_active Expired - Fee Related
-
2012
- 2012-05-10 JP JP2012108394A patent/JP5572665B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK1252192T3 (da) | 2006-11-20 |
| CN1406249B (zh) | 2010-06-16 |
| EP1252192A2 (de) | 2002-10-30 |
| CN1406249A (zh) | 2003-03-26 |
| CA2399832A1 (en) | 2001-08-16 |
| US20090264627A1 (en) | 2009-10-22 |
| NO20023774D0 (no) | 2002-08-09 |
| MXPA02007733A (es) | 2004-09-10 |
| US7091321B2 (en) | 2006-08-15 |
| JP2003522200A (ja) | 2003-07-22 |
| ES2269366T3 (es) | 2007-04-01 |
| HUP0204475A2 (en) | 2003-04-28 |
| DE60122286T2 (de) | 2007-08-02 |
| JP2012176969A (ja) | 2012-09-13 |
| US20020147311A1 (en) | 2002-10-10 |
| NO20023774L (no) | 2002-08-09 |
| JP5572665B2 (ja) | 2014-08-13 |
| WO2001058957A3 (en) | 2002-05-02 |
| PT1252192E (pt) | 2007-01-31 |
| US20060034836A1 (en) | 2006-02-16 |
| US7507406B2 (en) | 2009-03-24 |
| US7790415B2 (en) | 2010-09-07 |
| CY1105725T1 (el) | 2010-12-22 |
| EP1252192B1 (de) | 2006-08-16 |
| DE60122286D1 (de) | 2006-09-28 |
| WO2001058957A2 (en) | 2001-08-16 |
| JP5179689B2 (ja) | 2013-04-10 |
| AU4314801A (en) | 2001-08-20 |
| CA2399832C (en) | 2011-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE336514T1 (de) | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen | |
| DK1088084T3 (da) | Erythropoietin analog-humant serumalbumin fusionsprotein | |
| DE60238541D1 (de) | Modifizierte transferrin-fusionsproteine | |
| DE60333306D1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen | |
| BR0112111A (pt) | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina | |
| NO176575C (no) | Sammensmeltet gen, kloningsvektor, samt anvendelse av kloningsvektoren | |
| ATE159429T1 (de) | Methode zum überbringen von agenzien an zielzellen | |
| ATE316982T1 (de) | Mehrere zytokin-antikörper komplexen | |
| DE69408145D1 (de) | Hydrazine mit einer n3s konfiguration als radionukleide chelatoren | |
| YU66300A (sh) | Antitelo, specifično prema fap alfa, sa poboljšanom produktivnošću | |
| DE60232577D1 (de) | Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential | |
| ES2165851T3 (es) | Proteinas multivalentes que se unen a antigenos. | |
| BR9911549A (pt) | Processo de produção de fitase em levedura | |
| DE60032926D1 (de) | Verbesserung von peptid-transport durch konjugation mit gallensäuren | |
| ATE178053T1 (de) | N2s2-chelatoren des hydrazino-typs | |
| NO854460L (no) | Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter. | |
| WO2003065003A3 (en) | Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof | |
| GB9307371D0 (en) | Fusion proteins | |
| SE9403526D0 (sv) | New Peptides | |
| DK1032672T3 (da) | DNA19355-polypeptid, en tumornekrosefaktor-homolog | |
| DK0868435T3 (da) | Höjeffektivt vævsspecifikt forbindelsesindföringssystem ved anvendelse af streptavidin-protein A-fusionsprotein | |
| ES2114547T3 (es) | Anticuerpos monoclonales contra el virus de la hepatitis c. | |
| DK1539221T3 (da) | Transferrin-fusionsproteinbiblioteker | |
| ATE356831T1 (de) | Neuer galaninrezeptor | |
| DE69932644D1 (de) | Menschliches Protein mit in vitro antiproliferativer Aktivität. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1252192 Country of ref document: EP |